Beam Therapeutics Inc

-7.61 (-7.40%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)6.32B
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$9.59 Million
Adjusted EPS-$0.70
See more estimates
10-Day MA$102.71
50-Day MA$100.25
200-Day MA$90.41
See more pivots

Beam Therapeutics Inc Stock, NASDAQ:BEAM

26 Landsdowne Street, 2nd floor, Cambridge, Massachusetts 02139
United States of America
Phone: +1.857.327.8775
Number of Employees: 181


Beam Therapeutics, Inc. develops and commercializes DNA base editing technologies for the treatment of human disease. Its licensed technology platform, which includes access to base editing technologies and associated technologies that enhance the scope of base editing. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.